Médecins du Monde (MdM) and Treatment Action Group (TAG) are pleased to announce the launch of mapCrowd (www.mapCrowd.org), an innovative online resource and data collection platform for gathering and sharing hepatitis C information.
Ribavirin (RBV) is an HCV-fighting drug. RBV does not work by itself. Adding RBV to other drugs can increase the chance of being cured from HCV. In the United States, ribavirin is approved for children (3 to 18 years of age) and adults.
What is adherence? Adherence means sticking to something. It is often used to describe taking medicine without missing doses for as long as needed. Good adherence helps to maintain—or improve—your health. This fact sheet is about adherence to hepatitis C…
Olysio (simeprevir) is an HCV-fighting drug. It must be used with other drugs to treat hepatitis C. In the United States, Olysio is approved for people with hepatitis C genotype 1 who are over 18 years old.